Advertisement

Volume 134, Issue 11

 

 

September 12, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure:First demonstration of developmental path of precursor B-ALL. See the article by Bueno et al.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
The investigators used genomic techniques to interrogate a large series of neutrophilic myeloid neoplasms, including atypical chronic myeloid leukemia, chronic neutrophilic leukemia, and others. They identify unique mutation patterns and a detailed genomic landscape that suggest that the current clinicopathologically defined entities may not be biologically relevant.


Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
The results of this study show that chimeric antigen receptor (CAR) T-cell therapy with tisagenlecleucel, a CD19-specific CAR T-cell product, is a feasible option for patients with secondary central nervous system (CNS) diffuse large B-cell lymphoma, with limited toxicity and potential efficacy.


Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
This paper offers the first description of zanubrutinib, a new Bruton tyrosine kinase (BTK) inhibitor with an improved safety profile.


Natural history and cell of origin of TCF3-ZNF384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL
In a series of elegant studies, the investigators elucidate the developmental path of a TCF3-ZNF384/PTPN11–driven B-cell acute lymphoblastic leukemia (BCP-ALL) with different PTPN11 mutations. Through the analysis of a pair of identical twins, they formally demonstrate for the first time that TCF3-ZNF384 is a primary prenatal event; these results are relevant both for understanding the disease and for potential therapies.


Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients
Factor VIII (FVIII) pharmacokinetic (PK) properties show high interpatient variability in hemophilia A patients. This study evaluates how von Willebrand factor (VWF) genetic variants modify the PKs of FVIII and provides important new mechanistic insights in this area.


View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.